BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) – Equities researchers at HC Wainwright issued their FY2029 EPS estimates for shares of BriaCell Therapeutics in a report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.05) per share for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($1.39) per share.
BriaCell Therapeutics Stock Performance
Shares of BCTX stock opened at $0.65 on Friday. The stock’s 50-day simple moving average is $0.70 and its 200-day simple moving average is $1.55. The firm has a market capitalization of $11.87 million, a PE ratio of -0.52 and a beta of 1.31. BriaCell Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $6.36.
Institutional Trading of BriaCell Therapeutics
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
See Also
- Five stocks we like better than BriaCell Therapeutics
- Manufacturing Stocks Investing
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.